Horizon and Transgenomic to Collaborate on Genetic Diagnostic Tests

The collaboration will enable Transgenomic to transition from the use of plasmid-derived controls, to Horizon’s Quantitative Molecular Reference Standards for all of its existing assays, and for any new assays developed in the future.

Under the terms of the collaboration agreement, Horizon will provide its renewable, genetically defined Quantitative Molecular Reference Standards in both genomic DNA (gDNA) and formalin fixed paraffin embedded (FFPE) format, via its Horizon Diagnostics division. The Quantitative Molecular Reference Standards will be used as advanced reference standards for Transgenomic’s range of genetic diagnostic tests, and in the development of novel tests and in vitro diagnostic testing kits. The Quantitative Molecular Reference Standard products will be chosen from Horizon Diagnostics’ existing inventory of over 300 products, and Horizon’s GENESIS gene editing platform will also be employed to engineer new lines as needed, to support the development of the new tests and kits.

Paul Morrill, senior vice president of Horizon Diagnostics commented, “Transgenomic operates at the cutting edge of molecular diagnostics and is an ideal partner for Horizon. This collaboration adds to our strong network of world class partners practicing high quality science, and contributes to our goal of advancing personalized medicine and ultimately better patient care. We look forward to working with the Transgenomic team.”

Horizon Diagnostics’ Reference Standard product portfolio comprises validated, engineered cell line derived material, including purified DNA with matched normal and renewable formalin fixed, paraffin embedded samples. The available specimens cover a growing range of oncology biomarkers, manufactured to precise standards including defined allelic frequencies.

Related Links:
Horizon Discovery
Transgenomic